搜尋
Genmab A/S
GMAB添加自選
28.870USD
+0.230+0.80%
收盤 07-31 16:00（美東）報價延遲15分鐘
17.79B總市值
21.75本益比TTM
關於 Genmab A/S 公司
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.
Genmab A/S簡介
公司代碼GMAB
公司名稱Genmab A/S
上市日期Oct 01, 2000
CEOVan De Winkel (Jan G.J)
員工數量2682
證券類型Depository Receipt
年結日Oct 01
公司地址Carl Jacobsens Vej 30
城市VALBY
上市交易所NASDAQ OMX - NASDAQ BASIC
國家Denmark
郵編2500
電話4570202728
網址https://www.genmab.com/
公司代碼GMAB
上市日期Oct 01, 2000
CEOVan De Winkel (Jan G.J)
Genmab A/S公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Jan G.J. Van De Winkel, Ph.D.
Dr. Jan G.J. Van De Winkel, Ph.D.
President, Chief Executive Officer
President, Chief Executive Officer
--
--
Dr. Anders Gersel Pedersen, M.D., Ph.D.
Dr. Anders Gersel Pedersen, M.D., Ph.D.
Non-Independent Director
Non-Independent Director
--
--
Mr. Anthony Pagano
Mr. Anthony Pagano
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Dr. Paolo Paoletti, M.D.
Dr. Paolo Paoletti, M.D.
Independent Director
Independent Director
--
--
Ms. Pernille Lyngvold Erenbjerg
Ms. Pernille Lyngvold Erenbjerg
Independent Deputy Chairman of the Board
Independent Deputy Chairman of the Board
--
--
Ms. Martine J. Van Vugt, Ph.D.
Ms. Martine J. Van Vugt, Ph.D.
Executive Vice President, Chief Strategy Officer
Executive Vice President, Chief Strategy Officer
--
--
Dr. Judith V. Klimovsky, M.D.
Dr. Judith V. Klimovsky, M.D.
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
--
--
Mr. Rolf K. Hoffmann
Mr. Rolf K. Hoffmann
Independent Director
Independent Director
--
--
Ms. Deirdre P. Connelly
Ms. Deirdre P. Connelly
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Tahamtan (Tahi) Ahmadi, M.D., Ph.D.
Dr. Tahamtan (Tahi) Ahmadi, M.D., Ph.D.
Executive Vice President, Chief Medical Officer, Head of Experimental Medicines
Executive Vice President, Chief Medical Officer, Head of Experimental Medicines
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Jan G.J. Van De Winkel, Ph.D.
Dr. Jan G.J. Van De Winkel, Ph.D.
President, Chief Executive Officer
President, Chief Executive Officer
--
--
Dr. Anders Gersel Pedersen, M.D., Ph.D.
Dr. Anders Gersel Pedersen, M.D., Ph.D.
Non-Independent Director
Non-Independent Director
--
--
Mr. Anthony Pagano
Mr. Anthony Pagano
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Dr. Paolo Paoletti, M.D.
Dr. Paolo Paoletti, M.D.
Independent Director
Independent Director
--
--
Ms. Pernille Lyngvold Erenbjerg
Ms. Pernille Lyngvold Erenbjerg
Independent Deputy Chairman of the Board
Independent Deputy Chairman of the Board
--
--
Ms. Martine J. Van Vugt, Ph.D.
Ms. Martine J. Van Vugt, Ph.D.
Executive Vice President, Chief Strategy Officer
Executive Vice President, Chief Strategy Officer
--
--
常見問題
Genmab A/S的前五大股東是誰？
Genmab A/S的前五大股東如下：Dr. Jan G.J. Van De Winkel, Ph.D.
有多少機構持有Genmab A/S(GMAB)的股份？
截至2026Q1，共有564家機構持有Genmab A/S的股份，合計持有的股份價值約為74.31M，占公司總股份的12.10% 。與2025Q4相比，機構持股有所增加，增幅為-2989185.00。
哪個業務部門對Genmab A/S的收入貢獻最大？
在2026Q1，Royalties業務部門對Genmab A/S的收入貢獻最大，創收3.10B，占總收入的83.39% 。